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Corrections
MEDICAL SCIENCES.For the article ‘‘A live, attenuated recombinant
West Nile virus vaccine,’’ by Thomas P. Monath, Jian Liu,
Niranjan Kanesa-Thasan, Gwendolyn A. Myers, Richard Ni-
chols, Alison Deary, Karen McCarthy, Casey Johnson, Thomas
Ermak, Sunheang Shin, Juan Arroyo, Farshad Guirakhoo, Jef-
frey S. Kennedy, Francis A. Ennis, Sharone Green, and Philip
Bedford, which appeared in issue 17, April 25, 2006, of Proc.
Natl. Acad. Sci. USA (103, 6694–6699; first published April 14,
2006; 10.1073pnas.0601932103), the authors note that Fig. 5 did
not include all vaccine study groups. The corrected figure and
legend appear below. This error does not affect the conclusions
of the article.
Fig. 5. Cell-mediated immune responses after vaccinationwith ChimeriVax-WN02 andYF-VAX vaccines. (A)WNvirus-specific IFN-producing T cells permillion
PBMC. Open circle, placebo; inverted open triangle, YF-VAX; open squares, ChimeriVax-WN02 vaccine 5.0 log10 PFU; open diamonds, ChimeriVax-WN02 vaccine
3.0 log10 PFU. Dashed line represents cut-off value. (B) T lymphocyte proliferation responses to inactivated WN virus antigen, represented as stimulation index.
(C) Correlation between IFN- producing WN virus-specific T cells and stimulation index in ChimeriVax-West Nile vaccines 14 and 28 days after immunization.
Confidence intervals for Spearman’s rank correlation of log10 IFN- producing PBMC per million and log10 stimulation index were based on Fisher’s
transformation. On day 14, the correlation was 0.491 (95% CI, 0.231–0.686); on day 28, the correlation was 0.188 (95% CI: 0.112 to 0.456).
www.pnas.orgcgidoi10.1073pnas.0603218103








BIOCHEMISTRY. For the article ‘‘The crystal structure of SdsA1, an
alkylsulfatase from Pseudomonas aeruginosa, defines a third class of
sulfatases,’’ by Gregor Hagelueken, Thorsten M. Adams, Lutz
Wiehlmann,UteWidow,HaraldKolmar, BurkhardTu¨mmler,Dirk
W. Heinz, and Wolf-Dieter Schubert, which appeared in issue 20,
May 16, 2006, of Proc. Natl. Acad. Sci. USA (103, 7631–7636; first
published May 9, 2006; 10.1073pnas.0510501103), the authors
note that on page 7631, the first line of the second full paragraph
in the right column appears incorrectly, due to a printer’s error.
‘‘Wepresent the crystal structure of SdsA1 fromP. aeruginosa strain
PAO1 at 1.9 Å resolution, the class-III sulfatase’’ should read: ‘‘We
present the crystal structure of the class-III sulfatase SdsA1 from
P. aeruginosa strain PAO1 at 1.9 Å resolution.’’ This error does not
affect the conclusions of the article.
www.pnas.orgcgidoi10.1073pnas.0604082103
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West Nile (WN) virus is an important cause of febrile exanthem and
encephalitis. Since it invaded the U.S. in 1999, >19,000 human
cases have been reported. The threat of continued epidemics has
spurred efforts to develop vaccines. ChimeriVax-WN02 is a live,
attenuated recombinant vaccine constructed from an infectious
clone of yellow fever (YF) 17D virus in which the premembrane and
envelope genes of 17D have been replaced by the corresponding
genes of WN virus. Preclinical tests in monkeys defined sites of
vaccine virus replication in vivo. ChimeriVax-WN02 and YF 17D had
similar biodistribution but different multiplication kinetics. Prom-
inent sites of replication were skin and lymphoid tissues, generally
sparing vital organs. Viruses were cleared from blood by day 7 and
from tissues around day 14. In a clinical study, healthy adults were
inoculated with 5.0 log10 plaque-forming units (PFU) (n 30) or 3.0
log10 PFU (n  15) of ChimeriVax-WN02, commercial YF vaccine
(YF-VAX, n  5), or placebo (n  30). The incidence of adverse
events in subjects receiving the vaccine was similar to that in the
placebo group. Transient viremia was detected in 42 of 45 (93%) of
ChimeriVax-WN02 subjects, and four of five (80%) of YF-VAX
subjects. All subjects developed neutralizing antibodies to WN or
YF, respectively, and the majority developed specific T cell re-
sponses. ChimeriVax-WN02 rapidly elicits strong immune re-
sponses after a single dose, and is a promising candidate warrant-
ing further evaluation for prevention of WN disease.
clinical trial  non-human primate  yellow fever
West Nile (WN) virus (familyFlaviviridae) first appeared in theWestern Hemisphere in 1999, causing an outbreak in New
York City. In successive years, WN expanded its geographic range.
Over 19,000 human cases have been reported in the United States
(1). The spectrum of disease extends from a mild febrile exanthem
to fatal encephalitis. Mosquito control has failed to stop progression
of the disease. However, the introduction of vaccines for horses (2,
3) has controlled the veterinary disease. In late 1999, we initiated
development of a vaccine for humans.
ChimeriVax-WN02 is a live, attenuated chimeric vaccine derived
from an infectious clone of yellow fever (YF) 17D virus in which the
premembrane and envelope proteins of YF 17D virus have been
replaced by the corresponding genes of WN (4). The vector, YF
17D vaccine, is approved by regulatory authorities worldwide, and
has a 70-year history of use in 400 million persons (5). Three
mutations were introduced into the WN E gene at sites predicted
to reduce neurovirulence (4, 6), resulting in a highly attenuated
phenotype. The vaccine candidate was incapable of being trans-
mitted by mosquitoes (7). ChimeriVax-WN02 vaccine protected
hamsters against challenge with WT WN virus (8). In rhesus
macaques, the vaccine caused a transient viremia, induced neutral-
izing (N) Ab, and protected against intracerebral challenge with
WT WN virus (4).
Here, we report tests in monkeys that elucidate sites of virus
replication in vivo, and the results of a clinical trial of a vaccine
for prevention of human infection with WN virus.
Results
Safety, Immunogenicity, and Biodistribution in Non-Human Primates.
A study in cynomolgus macaques evaluated ChimeriVax-WN02 for
possible toxicity, determined sites of virus replication in vivo, and
determined the relationship between N Ab response and viral
clearance. Groups of monkeys lacking detectable flavivirus hem-
agglutination-inhibiting Abs and Japanese encephalitis, WN, and
YF N Abs were inoculated s.c. with 0.5 ml of ChimeriVax-WN02
(5 log10 plaque-forming units, PFU), YF-VAX (5 log10 PFU), or
diluent. There were no clinical signs or changes in food consump-
tion, body weight, serum chemistry, hematology, or coagulation
parameters. Five animals per group were necropsied on days 7, 14,
and 46. There were no histological changes in any organ. Cerebro-
spinal fluid from ChimeriVax-WN02 treated monkeys on days 14
and 46 were negative for WN IgM Abs by ELISA, whereas serum
samples were positive for IgM Ab, indicating that the vaccine virus
had not invaded the CNS.
ChimeriVax-WN02 virus was detected in sera of 14 of 15 (93%)
monkeys. The mean peak viremia (SD) was 474 (230.4) PFU
ml, and the mean number of viremic days was 3.7 (1.3). YF 17D
virus was detected in sera of 7 of 15 (47%) monkeys. The mean peak
viremia (SD) was 67.3 (94.8) PFUml, and the mean number
of viremic days was 1.4 (1.6). Although the viremia levels were low
in both groups (Fig. 1A), the number of viremic days and the peak
titer were higher in monkeys receiving ChimeriVax-WN02 than
YF-VAX (P  0.0002 and P  0.0001, respectively; ANOVA). N
Abs were detected on day 7 in a higher proportion of monkeys
inoculated with YF-VAX [12 of 15 (80%) positive for YF N Abs]
than in those inoculated with ChimeriVax-WN02 [6 of 15 (40%)
positive for WN N Abs; P 0.0604, Fisher’s exact test, two-tailed];
however, by day 14 (as virus was clearing from tissues), 100% of the
animals in both groups had N Ab responses against the virus
inoculated (Fig. 1B).
To evaluate the safety implications of the earlier and higher
viremia in monkeys, we used quantitative RT-PCR to determine
sites of replication of the two viruses 3 days (n 4 per group), and
7, 14, and 46 days (n 5 per group) after inoculation. ChimeriVax-
WN02 was detected earlier than YF-VAX (Table 1), but the sites
of replication were similar, with a predilection for lymph nodes and
spleen. ChimeriVax-WN02 was found in skin at the site of inocu-
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lation (but not in the contralateral arm) at high virus loads in three
of four animals on day 3 (viremic period), and appeared to be
(together with lymph nodes) the principal contributor to viremia.
One ChimeriVax-treated animal had viral RNA in kidney on day
3. The higher viremia in monkeys inoculated with ChimeriVax-
WN02 appeared to be due to the higher replication in skin and
lymphoid tissues before the onset of immune clearance. On days 7
and 14, the viral burden in tissues of YF-VAX-treated animals
exceeded that in ChimeriVax-WN02-treated animals. No virus was
detected in liver, spinal cord, adrenal gland, or brain of any
ChimeriVax-WN02 treated and most YF-VAX-treated animals.
Virus RNA was detected on day 7 in the thymus, adrenal gland, and
liver of one of the five YF-VAX-vaccinated monkeys. By day 14,
virus RNA was present only in lymphoid tissues, and by day 46,
clearance was complete for both viruses. Virus loads were generally
low for both viruses, in the range of 50–500 PFU equivalents (eqg).
Plaque assays were consistent with quantitative RT-PCR (data not
shown).
Clinical Trial Comparing ChimeriVax-West Nile and YF-VAX. A ran-
domized, double-blind, placebo-controlled study in healthy male
and female adults 18–40 years was performed under an Investiga-
tional New Drug application. An initial cohort of 15 subjects
received 5.0 log10 PFU of ChimeriVax-WN02, whereas five controls
received YF-VAX. A second cohort of 15 subjects received 5.0 log10
PFU of ChimeriVax-WN02, and 15 received placebo. In a third
cohort, 15 subjects received a lower dose (3.0 log10 PFU) of
ChimeriVax-WN02, and 15 subjects received placebo. Subjects
were tested at baseline for N Abs to flaviviruses (WN, YF, St. Louis
encephalitis, and dengue types 1–4). Immunogenicity was assessed
in flavivirus-naı¨ve subjects.
There were no significant differences between groups in demo-
graphic or baseline characteristics. Viremia was detected by plaque
assay in 90%, 100%, 80%, and 0% of subjects in the ChimeriVax-
WN02 5.0 log and 3.0 log, YF-VAX, and placebo groups, respec-
tively. The mean duration of viremia was 5.1, 4.7, and 3.6 days in
these groups, respectively (Fig. 2). Mean daily viremia levels for all
three groups were low (100 PFUml). The mean area under the
curve for the low dose (3.0 log) ChimeriVax-WN02 group (311.7
PFUml per day) was statistically higher than for the high dose (5.0
log) group (173; P 0.0288, ANOVA). Viremia was cleared by day
10 (Fig. 2).
Most subjects reported at least one adverse event (AE) (Fig. 3),
but the incidence was similar across active and placebo recipients.
There was no relationship between viremia level and the occur-
rence or severity of AEs. Only one subject (ChimeriVax-WN02 3.0
log group) had a mild elevation in body temperature (38.2°C) as an
AE (on day 6). Two subjects with high elevations of creatine
phosphokinase, one in the ChimeriVax-WN02 5.0 log and one in
the YF-VAX group, were the subject of an intensive investigation
concluding that the enzyme elevations were likely due to muscle
injury from strenuous physical exercise rather than to the study
vaccines (9).
Fig. 1. ChimeriVax-WN02 or YF-VAX
were inoculated s.c. into cynomolgus ma-
caques. (A) Viremia mean (SD) by day
after inoculation of macaques with 5 log10
PFU ChimeriVax-WN02 or YF-VAX. (B) Neu-
tralizing Ab GMT.
Table 1. Biodistribution of ChimeriVax-WN02 and YF-VAX in tissues of cynomolgus monkeys by day after inoculation
Tissue

















Pos Eqml Pos Eqml Pos Eqml Pos Eqml Pos Eqml Pos Eqml Pos Eqml Pos Eqml
Skin
inoc 3 376, 408, 2850 1 78 0 1 126 0 0 0 0
contra 0 0 0 0 0 0 0 0
Spleen 0 0 0 4 59, 176, 234, 257 0 3 47, 69, 391 0 0
Lymph N
Axillary 1 110 1 246 1 242 2 102, 167 0 1 109 0 0
Mandib 2 301,963 0 1 281 2 49, 164 0 0 0 0
Mesen 0 1 338 1 87 1 97 0 3 84, 86, 199 0 0
Thymus 0 0 0 1 3632 0 0 0 0
Bone marrow 0 1 75 1 650 2 52, 141 0 0 0 0
Liver 0 0 0 1 34 0 0 0 0
Heart 0 0 0 0 0 0 0 0
Kidney 1 399 0 0 0 0 0 0 0
Pancreas 0 0 0 0 0 0 0 0
Adr gland 0 0 0 1 25 0 0 0 0
Skel muscle 0 0 0 0 0 0 0 0
Brain 0 0 0 0 0 0 0 0
CV-WN, ChimeriVax-WN02; YF, yellow fever 17D; Pos, number monkeys positive by PCR; Eqml, plaque-forming equivalents per ml; inoc, inoculation site;
contra, contralateral arm; mandib, mandibular; mesen, mesenteric; skel, skeletal.











On day 10, 7.1% (2 of 28) subjects vaccinated with 5.0 log10 PFU
ChimeriVax-WN and none of those receiving 3.0 log10 PFU sero-
converted. On day 21, the rate of seroconversion was 100% in both
ChimeriVax-WN02 treatment groups and high N Ab titers were
present (Fig. 4 and Table 2). In the ChimeriVax-WN02 3.0 log10
PFU group, one subject’s low titer (40) on day 21 dropped to 10 and
thus did not meet the definition of seroconversion on day 28. The
geometric mean N Ab titers were, respectively, 6,241 and 11,392 in
the 5.0 and 3.0 log10 PFU dose groups on day 21, and 1,280 and
1,218 on day 28. There was no significant difference in N Ab
seroconversion rate (P 1.0) or geometric mean titer (GMT) (P
0.914) across the high and low dose groups on day 28. Moreover,
there was no correlation between viremia (area under the curve)
and N Ab response (data not shown). YF-VAX elicited a YF-
specific N Ab response in five of five (100%) of subjects, with a
GMT of 3,880 on day 28. YF-VAX failed to elicit a cross-reactive
WN N Ab response except in one subject, who developed a low titer
(20) on day 21, but was seronegative by day 28.
Serum samples were obtained 3, 6, and 12 months after vacci-
nation. Thirty-five of 36 (97.2%) of ChimeriVax-WN02 vaccinated
subjects tested at 12 months were seropositive and retained high
titers of N Ab (Fig. 4). One subject (in the ChimeriVax-WN02 3.0
log10 PFU group) seroreverted between day 28 and 3 months; this
subject was still seronegative at 6 months, but had a N Ab titer of
1,280 at 12 months.
T Cell Responses. Nearly all recipients of ChimeriVax-WN02 vaccine
[28 of 30 (93.3%) and 15 of 15 (100%) in the 5.0 log and 3.0 log dose
groups, respectively; P 0.55, ANOVA] developed specific IFN-
producing cells in ELISPOT assays after restimulation with WN E
peptide pools. In contrast, only 1 of 5 YF-VAX and 0 of 10 placebo
recipients responded to WN (P 0.001 vs. ChimeriVax-WN02 dose
groups). High geometric mean levels of IFN--producing cells per
million peripheral blood mononuclear cells (PBMCs) were found in
the ChimeriVax-WN02 5.0 and 3.0 log dose groups on days 14 [78.1
(95% CI, 55.3–110.4) and 118.0 (95% CI, 80.8–172.2), respectively]
and on day 28 [93.8 (95% CI, 63.8–137.9) and 91.9 (95% CI,
62.3–135.6)] (Fig. 5A). Interestingly, a later maximal IFN- re-
sponse was associated with a longer duration of viremia and greater
number of days of viremia, but showed no correlations with
maximal viremia titer, area under the viremia curve, or N Ab titer.
WN-specific T cell proliferative responses were detected in
PBMC from 25 of 30 (83%) and 13 of 15 (87%) of ChimeriVax-
WN02 5.0 log and 3.0 log10 PFU recipients, 3 of 5 (60%) of
YF-VAX recipients, and 0 of 10 placebo recipients (Fig. 5B). The
maximal SI was measured on day 14 in 8 of 25 (32%) and 4 of 13
(31%), and on day 28 in 17 of 25 (68%) and 9 of 13 (69%) of
ChimeriVax-WN02 5.0 and 3.0 log dose vaccinated subjects with
detectable T lymphocyte lymphoproliferation responses. Individu-
als with a later maximal proliferation response had higher maximal
viremia levels, higher area of viremia under the curve (280.58 
306.44 for day 28 maximal responders vs. 102.92  105.39 for day
14; P 0.02, Kruskal–Wallis Rank Sum), and a greater number of
viremic days. T lymphocyte proliferative responses were detected in
one YF-VAX vaccinated subject on day 0. This response was not
detectable on day 14, but reappeared on day 28 for this individual.
Similarly, one ChimeriVax-WN02 5.0 log dose recipient who was
Ab seronegative had detectable IFN- responses to WN virus
peptides on day 0. This volunteer developed WN-specific T cell
proliferative responses on day 28 (SI 12.3). It is possible that these
donors might be immune to a flavivirus that was not tested in Ab
assays.
Concordance of WN virus-specific IFN- ELISPOT and T
lymphocyte proliferation assays in ChimeriVax-WN02 recipients
was stronger on study day 14 (9 of 14 volunteers, 64%) than on study
day 28 (4 of 14 volunteers, 29%) [r 0.491 (95% CI, 0.231–0.686)
and r 0.188 (95% CI,0.112 to 0.456), respectively] (Fig. 5C). T
cell responses were detected by both assays on either day 14 or 28
in 25 of 30 (83%), 13 of 15 (87%), and one of five (20%) subjects
in the 5.0 and 3.0 log10 PFU dose ChimeriVax-WN02 vaccine and
YF-VAX groups.
Discussion
The in vivo replication of virulent, WT YF virus has been studied
in monkeys (10). WT virus spreads from Kupffer cells to paren-
chyma of the liver, with severe coagulative necrosis of hepatocytes.
In contrast, YF 17D vaccine does not cause liver damage. There are
no previous data on the sites of replication of YF 17D vaccine.
Studies of other flaviviruses suggest that the initial site of replica-
Fig. 3. Incidence of AEs occurring at rate10% in the ChimeriVax-WN02 or
placebo groups.
Fig. 2. Clinical trial of ChimeriVax-WN02: Viremia mean PFUml (SD) by
day after s.c. inoculation with 5.0 or 3.0 log10 PFU ChimeriVax-WN02 or
YF-VAX.
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tion is skin at the site of inoculation (11, 12), specifically Langer-
hans’ cells (LC) (13), and that activated LC migrate to draining
lymph nodes under the control of IL-1 (14), where additional
replication occurs and antigen processing is initiated (15). The virus
is believed to reach the blood stream via efferent lymphatics and the
thoracic duct (16). Viremia is cleared from the blood by N Abs, but
replication continues for a longer period in tissues pending eventual
clearance by cytotoxic T lymphocytes (11). Our data are consistent
with these observations. An important concern was the higher
viremias seen in monkeys inoculated with ChimeriVax-WN02 than
with YF-VAX, but this was associated only with early replication of
virus in skin (inoculation site) and lymph nodes. Indeed, the viral
load in tissues was higher for YF-VAX than ChimeriVax-WN02. It
is noteworthy also that another monkey species (rhesus) showed YF
17D viremia exceeding that of ChimeriVax-WN (4). Virus may
invade the CNS via the bloodstream, but none of the monkeys in
either group developed CNS infections. Moreover, ChimeriVax-
WN02 is significantly less neurovirulent after direct intracerebral
inoculation than YF 17D virus (4). One of four monkeys examined
on day 3 had ChimeriVax-WN02 RNA in kidney, but no animal at
later time points had renal infection and did not develop chronic
renal infection as described in hamsters infected with WT WN
virus (17).
In a clinical trial, ChimeriVax-WN02 was well tolerated, and
there were no differences in the incidence of AE reports compared
to the placebo group. With 45 subjects receiving ChimeriVax-
WN02 in the study, if a certain AE is not observed, there is a
confidence level of 95% that the actual rate of that event is at most
6.7%. Future studies will address safety and tolerability for elderly
and infirm persons at greatest risk of severe WN virus disease (18).
Nearly all subjects experienced a transient low viremia, an expected
observation with YF 17D (5) and other chimeric vaccines (19).
Subjects who received the lower (3 log10 PFU) dose of ChimeriVax-
WN02 had statistically higher viremias than those receiving a dose
100 times higher. This paradoxical response has been observed in
the case of YF 17D vaccine (5) and a chimeric vaccine against
Japanese encephalitis (19) and may be due to a lower innate and
delayed adaptive immune response to the lower dose. Control of the
early phase of flavivirus infection depends on type 1 IFN synthesis
by plasmacytoid DC (20). Viremia after YF 17D vaccination is
accompanied by detectable levels of cytokines reflecting toll-like
receptor mediated signaling (21–24). It is postulated that the mild
systemic side effects of YF 17D vaccine are associated with release
of these cytokines (24) and that the strong innate immune responses
to YF 17D shape the robust and durable adaptive immune response
to this vaccine (25).
Neutralizing Abs are the principal mediators of protective im-
munity against flaviviruses. After a single dose, all subjects given
ChimeriVax-WN02 developed high titers of WN-specific N Abs by
day 21. Interestingly, only two (7.1%) subjects given ChimeriVax-
WN02 5.0 logs had N Abs on day 10. In contrast, YF 17D vaccine
is well known to induce N Abs in 80–90% of human subjects by day
10 (5). The slower appearance of Abs after ChimeriVax-WN02 may
provide a partial explanation for the higher viremia observed, and
it may in turn be linked to a different innate immune response to
the chimeric vaccine compared to YF-VAX. In cynomolgus mon-
keys, the N Ab response to YF 17D and ChimeriVax-WN02 was
more rapid than in humans, with 80% of animals becoming
seropositive by day 7 (Fig. 1B).
CD8 T cells play a crucial role in recovery from WNV infection
(26). In the clinical trial, we detected WN virus-specific T-cell
responses in 93% and 100% of subjects inoculated with Chimeri-
Vax-WN02 5.0 log and 3.0 log, respectively, whereas a low number
of IFN--producing T cells to WN virus peptides was found in only
one of five and T lymphocyte proliferative responses in three of five
YF-VAX recipients. This number likely represents an underesti-
mate of the true frequency of induction of WN-specific T cell
responses, because the ELISPOT assay was performed by using
pools of 20-mer peptides. Peptide length, distribution of epitopes
within a peptide, and the number of peptides in the pools can
influence sensitivity of the ELISPOT assay (27, 28). The number of
WN virus-specific T cells was measured by using only peptides to
the E protein; on the other hand, the proliferation assay uses an
inactivated antigen made from WN virus-infected cells and con-
Fig. 4. Individual neutralizing Ab responses to WN virus in the 5.0 or 3.0 log10 PFU ChimeriVax-WN02 treatment groups by interval after inoculation. See Table 2.
Table 2. Clinical trial: Proportion seropositive and geometric mean antibody titers
Group Statistic Day 21 Day 28 Month 3 Month 6 Month 12
5.0 log Seropositive 2828 (100%) 2728 (96%) 2626 (100%) 2121 (100%) 1919 (100%)
GMT 6,241 1,280 2,182 1,122 595
3.0 log Seropositive 1313 (100%) 1414 (100%) 910 (90%) 67 (86%) 55 (100%)
GMT 11,392 1,218 1,194 525 640











tains all viral structural and nonstructural proteins. Based on
experience with other viruses, such as HIV (27, 29), the WN virus
E peptide-specific IFN- responses may largely represent WN-
specific CD8 T cells, although this was not specifically demon-
strated. These results are consistent with studies of lymphocytic
choriomeningitis virus in mice and vaccinia in humans demonstrat-
ing that effector CD8 T lymphocytes expand upon antigen stim-
ulation and contract again after the acute phase of infection
(30, 31).
The structural genes of divergent mosquito-borne flaviviruses
such as WN and YF viruses have a lesser degree of homology (32).
However, the inactivated WN antigen preparation contains WN
nonstructural proteins with both specific and cross-reactive
epitopes that induce a CD4 T lymphocyte response (33, 34). As a
result, the T lymphocyte proliferation assays are probably detecting
not only WN virus-specific CD4 responses, but also cross-reactive
responses against the more conserved nonstructural regions of WN
and YF viruses. Therefore, it is not surprising that we found some
disparity between the WN virus E specific IFN--producing T cells
and the T lymphocyte proliferative responses in the two vaccine
groups.
We detected a significant association between the duration of
viremia and maximal IFN- and proliferation responses in recipi-
ents of ChimeriVax-WN02 regardless of vaccine dose. Later max-
imal T cell proliferative responses were also associated with higher
maximal viremia levels and area under the viremia curve. CD8 T
cells play an important role in destroying infected cells, and CD4
T cells help Ab producing B cells and CD8 T cells to proliferate.
Immunization with ChimeriVax-WN02 may lead to the generation
of a spectrum of WN virus-specific T cell repertoires of differing
avidity, which control infection with vaccine virus and later, after
challenge with WN virus, in nature.
In summary, ChimeriVax-WN-WN02 vaccine induces high levels
of N Abs and CD4 and CD8 T cell responses against WN virus
in nearly all human volunteers within 14–28 days of vaccine
administration. Such a vaccine could be useful in preventing illness
and limiting outbreaks of WN virus infection. Further clinical trials
to define vaccine safety and immunogenicity are warranted.
Materials and Methods
Viruses and Cell Lines. The construction of ChimeriVax-WN02
vaccine has been described (4). Mutations were introduced into the
WN E codons E107 (L3 F), E336 (A3 V), and E440 (K3 R).
Chimeric RNA was transfected to Vero cells by electroporation.
Progeny virus was amplified under serum-free conditions, and
supernatant fluid was harvested to produce a master virus seed
[passage 3 (P3)], production seed (P4), and vaccine (P5) according
to current good manufacturing practices. The P5 vaccine lot was
manufactured in a 100-liter bioreactor using cells grown on micro-
carrier beads. The full genomic sequence of P4 and P5 verified that
all three introduced E protein mutations were intact and that no
other genetic changes had occurred. The virus was purified and
concentrated by nuclease digestion (to cleave host cell DNA), depth
filtration, ultrafiltration, and diafiltration.
WT WN virus used in animal challenge studies is the NY99 strain
(NY99–35262-11 flamingo isolate, Centers for Disease Control,
Fort Collins, CO) with two additional passages in Vero E6. YF 17D
commercial vaccine (YF-VAX, Sanofi-Pasteur, Swiftwater, PA)
was used without passage (human and monkey studies) or after one
passage in Vero cells for T cell and N Ab tests.
Viremia and Neutralizing Antibody Measurements. Virus in serum
and tissues was measured by plaque assay in Vero cell monolayers
in 12-well plates. After inoculation, cells were overlaid with methyl
cellulose, incubated at 37°C for 5 days, fixed with formaldehyde, and
stained with 1% crystal violet. Fifty-percent plaque reduction N
tests were performed in Vero cell monolayers as described (35). In
the study of cynomolgus monkeys, the YF N test was a constant
serum, varying virus assay in Vero cell monolayers. The result is
expressed as a log10 neutralization index with a cut-off for a positive
result of 0.7.
Quantitative Assessment of Tissue Virus by PCR. The study was
conducted to Good Laboratory Practices. Monkeys received a
single s.c. injection and were evaluated for clinical signs, changes in
food consumption and injection site appearance, and changes in
body weight. Blood samples were collected on day 0, and on days
2, 4, 6, 10, 14, 28, and 46 for chemistry, hematology, and coagulation
tests. Serum was collected on days 0–10 for viremia, and on days 7,
14, 30, and 46 for N Ab tests. At necropsy on days 7, 14, and 46,
cerebrospinal fluid was collected, the monkeys were perfused with
sterile isotonic saline, and a complete necropsy performed.
Monkey tissues were homogenized in 300 l of PBS (for plaque
assays) or Buffer RLT (Qiagen, Valencia, CA) for quantitative
PCR. Virus RNA was detected in duplicate or triplicate reactions
by quantitative PCR assay using virus RNA standards made from
Fig. 5. Cell-mediated immune responses after vaccination with ChimeriVax-WN02 and YF-VAX vaccines. (A) WN virus-specific IFN-producing T cells per million
PBMC. Open diamonds, ChimeriVax-WN02 vaccine 5.0 log10 PFU; open squares, ChimeriVax-WN02 vaccine 3.0 log10 PFU; inverted open triangle, YF-VAX; open
circle, placebo. (B) T lymphocyte proliferation responses to inactivated WN virus antigen, represented as stimulation index. (C) Correlation between IFN-
producing WN virus-specific T cells and stimulation index in ChimeriVax-West Nile vaccines 14 and 28 days after immunization. Confidence intervals for
Spearman’s rank correlation of log10 IFN- producing PBMC per million and log10 stimulation index were based on Fisher’s transformation. On day 14, the
correlation was 0.491 (95% CI, 0.231–0.686); on day 28, the correlation was 0.188 (95% CI: 0.112 to 0.456).
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infected lysate of Vero cells. Standards were amplified in triplicate
along with test samples on each reaction plate. The primer and
probe set was designed to anneal to sequence shared by Chimeri-
Vax-WN02 and YF 17D viruses. The forward primer was at
nucleotide positions 340–362, and the reverse primer bounded to
nucleotides 424–445. The probe labeled with FAM at the 5 end
and TARMA at the 3 end annealed to the virus genome at
nucleotides 376–403 of YF-17D and ChimeriVax-WN02 virus.
Reactions were carried out as one-step quantitative PCR reactions
using the ABI PRISM 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA) in 1	TaqMan Universal PCR Master
Mix without AmpErase UNG, 1	 Multiscribe and RNase Inhibi-
tor, 100 M probe, 200 nM forward primer, and 200 nM reverse
primer. After the initial reverse transcription reaction at 48°C for 30
min and an intermittent incubation at 95°C for 10 min, reactions
were completed by 40 cycles of amplification at 95°C for 15 s and
60°C for 1 min. PFU equivalent was calculated according to the
virus RNA standards run on the same reaction plate. A signal level
between negative and lowest point of the standard curve was
considered nonquantifiable (‘‘equivocal’’).
T Cell Assays. WN virus antigen was prepared as a single lot in
Vero cells as described (36). Control antigen was prepared in a
similar fashion by using uninfected Vero cells.
Quantitation of WN-Specific IFN- Producing T Cells. IFN- ELIS-
POT assays were performed with modifications to the procedure
described in refs. 27 and 37. Briefly, cryopreserved PBMCs were
thawed, washed, plated (250,000 cells per well), and stimulated
in triplicate with four pools of 20-mer peptides (Mimotopes,
Victoria, Australia) overlapping by 10 amino acids correspond-
ing to the E sequence of WN NY-99. Plates were read by a single
reader on a microscope or by automated ELISPOT reader. A
cutoff value of 43 spots per million PBMC was calculated as
mean 2 SD of the sum of the day 0 E pool responses. The mean
day 0 response for each peptide pool was low (five spots per
million PBMC).
WN-Specific T Lymphocyte Proliferation Assay. Assays were per-
formed in replicates of five as described (36) using inactivated
WN virus antigen as stimulant, phytohemagglutinin as positive
control, and mock-infected Vero cell lysate as negative control.
Stimulation indices were calculated after eliminating the high
and low value for each replicate of five as follows: mean cpm WN
virus antigenmean cpm control antigen. A positive response
was a stimulation index  3.
Statistical Methods.Differences in mean log10 peak IFN- responses
and mean log peak stimulation indices as well as associations
between IFN- responses and T lymphocyte proliferation responses
and parameters related to viremia and neutralizing Abs were
assessed by using a Kruskal–Wallis Rank Sum test. For the clinical
trial, statistical comparison of treatment groups used logistical
regression methods for seroconversion rates and ANOVA for
GMTs.
Clinical Trial. The double-blind trial was performed at a single center
(PRA International, Lenexa, KS) under a protocol approved by an
Institutional Review Board. Exclusion criteria included history of
military service or travel to tropical flavivirus-endemic areas,
immune suppression, egg allergy, positive hepatitis or HIV tests,
pregnancy, lactation, significant medical or psychiatric disorders,
and abnormal baseline clinical laboratory tests. On day 0, eligible
subjects received a s.c. inoculation of 0.5 ml of ChimeriVax-WN02,
YF-VAX, or placebo (50 mM Tris0.85% NaCl10% sorbitol in
water for injection) (see Results). Subjects took daily oral temper-
ature, completed a symptom diary, and returned to the clinic on
days 1–14, 21, and 28 for determination of AEs. Blood was taken
on days 0–14 and 21 for viremia, on days 0, 10, 21, and 28 for Ab
tests, and on days 0, 14, and 28 for T cell studies. Viremia duration
was calculated as the last visit date on which the subject had
detectable viremia minus the first date of detectable viremia (plus
1 day); area under the curve for the period days 1–14 was calculated
by using the linear trapezoidal method. The primary efficacy
endpoint was the proportion of subjects who were seronegative at
baseline and who developed  4-fold rises in N Abs on day 28.
Secondary endpoints were GMT and T cell responses.
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